BVX-130-mcMMAF

N/A

Report date: 2024/02/05 14:00:30

Base Information

Drug NameBVX-130-mcMMAF

Drug Alias NameBVX-130-mcMMAFBVX130-mcMMAF

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsTubulin polymerisation inhibitors

TargetsMyeloid cell surface antigen CD33T-cell antigen CD7Tubulin

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiVictriX Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBiVictriX Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A